Literatur
-
1
Corley S D, Epstein A E, DiMarco J P. et al .
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.
Circulation.
2004;
109
1509-1513
-
2
Healey J S, Baranchuk A, Crystal E. et al .
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
J Am Coll Cardiol.
2005;
45
1832-1839
-
3 Hohnloser S H. Hotline Session. European Society of Cardiology Congress. Munich 2004
-
4
Lafuente-Lafuente C, Mouly S, Longas-Tejero M A, Mahe I, Bergmann J F.
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Arch Intern Med.
2006;
166
719-728
-
5
Madrid A H, Bueno M G, Rebollo J M. et al .
Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.
Circulation.
2002;
106
331-336
-
6 Sanofi-Synthelabo. Pressemitteilung zum Abbruch des Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease. ANDROMEDA 2003
-
7
Steinberg J S, Sadaniantz A, Kron J. et al .
Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
Circulation.
2004;
109
1973-1980
-
8
Wachtell K, Lehto M, Gerdts E. et al .
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
J Am Coll Cardiol.
2005;
45
712-719
Prof. Dr. med. Uwe K. H. Wiegand
Universitätsklinikum Schleswig-Holstein Campus Lübeck, Medizinische Klinik II
Ratzeburger Allee 160
23538 Lübeck
Email: uwe.wiegand@medinf.mu-luebeck.de
